In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained Streptococcus pyogenes isolates

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2406-2408

  Pérez Trallero, Emilio ^a,b,c   Tamayo, Esther ^a   Montes, Milagrosa ^a,b   García Arenzana, José M ^b   Iriarte, Victor ^d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACITRACIN; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; JOSAMYCIN; LINCOMYCIN; NEOMYCIN; NORFLOXACIN; PENICILLIN G; PSEUDOMONIC ACID; RETAPAMULIN; TETRACYCLINE; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL SKIN DISEASE; BACTERIUM ISOLATION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG USE; ENDOLYMPH; GROUP A STREPTOCOCCAL INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARYNX; PRIORITY JOURNAL; SKIN; STREPTOCOCCUS PYOGENES; TOPICAL TREATMENT;

ANTI-INFECTIVE AGENTS; BACITRACIN; BICYCLO COMPOUNDS, HETEROCYCLIC; CIPROFLOXACIN; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; STREPTOCOCCUS PYOGENES; TETRACYCLINE;

EID: 79955544018     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01665-10     Document Type: Article

References (19)

1. Brian, M. J. 2010. Mupirocin-resistant MRSA transmission associated with community hospitals and nursing homes. J. Hosp. Infect. 75:141-142.
2. Castanheira, M., A. A. Watters, R. E. Mendes, D. J. Farrell, and R. N. Jones. 2010. Occurrence and molecular characterization of fusidic acid resistance mechanisms among Staphylococcus spp. from European countries (2008). J. Antimicrob. Chemother. 65:1353-1358.
3. Chan, J. C., Y. W. Chu, M. Y. Chu, T. K. Cheung, and J. Y. Lo. 2009. Epidemiological analysis of Streptococcus pyogenes infections in Hong Kong. Pathology 41:681-686.
4. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Kosowska-Shick, K., et al. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769.
6. McDougal, L. K., et al. 2010. Emergence of resistance among USA300 methicillin-resistant Staphylococcus aureus isolates causing invasive disease in the United States. Antimicrob. Agents Chemother. 54:3804-3811.
7. Mihaila-Amrouche, L., A. Bouvet, and J. Loubinoux. 2004. Clonal spread of emm type 28 isolates of Streptococcus pyogenes that are multiresistant to antibiotics. J. Clin. Microbiol. 42:3844-3846.
8. Montes, M., E. Tamayo, B. Orden, J. Larruskain, and E. Pérez-Trallero. 2010. Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain. Antimicrob. Agents Chemother. 54:93-97.
9. Moody, M. N., L. K. Morrison, and S. K. Tyring. 2010. Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis? Skin Therapy Lett. 15:1-4.
10. Pankuch, G. A., et al. 2006. Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies. Antimicrob. Agents Chemother. 50:1727-1730.
11. Pérez-Trallero, E., C. Garcia, B. Orden, J. M. Marimon, and M. Montes. 2004. Dissemination of emm28 erythromycin-, clindamycin- and bacitracin-resistant Streptococcus pyogenes in Spain. Eur. J. Clin. Microbiol. Infect. Dis. 23:123-126.
12. Pérez-Trallero, E., et al. 2010. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007). Antimicrob. Agents Chemother. 54:2953-2959.
13. Pérez-Trallero, E., et al. 2007. Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in Spain, 1999 to 2005. Antimicrob. Agents Chemother. 51:1228-1233. (Pubitemid 46586798)
14. Pires, R., et al. 2005. Group A streptococci from carriage and disease in Portugal: evolution of antimicrobial resistance and T antigenic types during 2000-2002. Microb. Drug Resist. 11:360-370. (Pubitemid 43099774)
15. Pires, R., et al. 2009. Resistance to bacitracin in Streptococcus pyogenes from oropharyngeal colonization and noninvasive infections in Portugal was caused by two clones of distinct virulence genotypes. FEMS Microbiol. Lett. 296:235-240.
16. Rittenhouse, S., et al. 2006. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. 50:3882-3885.
17. Stevens, D. L., et al. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41:1373-1406.
18. Swartz, M. N., and M. S. Pasternack. 2005. Cellulitis and subcutaneous tissue infections, p. 1172-1194. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 6th ed. Churchill Livingstone Elsevier, Philadelphia, PA.
19. Traczewski, M. M., and S. D. Brown. 2008. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother. 52:3863-3867.